INTRODUCTION
Although Streptococcus pneumoniae infections begin as asymptomatic nasopharyngeal colonization, this organism is the most common bacterial cause of community-acquired pneumonia (E20-30% of cases), purulent otitis media (10-25%), and sinusitis. [1] [2] [3] [4] As an invasive pathogen, the pneumococcus is the leading cause of bacteremic pneumonia (E65%) and bacterial meningitis (430%), 5 with X20,000 deaths per year in the United States 6 and up to a million deaths worldwide. 7 The functional interplay between bacterial virulence factors and host immune responses likely determines whether S. pneumoniae causes asymptomatic colonization, isolated mucosal infection, or invasive disease.
In both the blood and upper respiratory tract, immunoglobulin A1 (IgA1) comprises E90% of total IgA, whereas IgA2 accounts for only E10%. 8, 9 Human IgA1 is cleaved by highly host species-specific proteases produced by S. pneumoniae and several other invasive mucosal pathogens (e.g., Neisseria species and Haemophilus influenzae). Cleavage results in dissociation of the effector function of the Fc fragment of bound IgA1 from its antigen-binding Fab fragments, [10] [11] [12] [13] [14] a process shown to promote adherence of S. pneumoniae to respiratory epithelial cells in vitro. 15 IgA1 protease had been proposed, [16] [17] [18] [19] and, more recently, shown in vitro to abrogate the protective effects of human IgA1, 20 effects that include complement-dependent killing of the organism by phagocytes. However, because of the species-and subclassspecificity of the protease and the previous unavailability of purified IgA1 and IgA2 of comparable antigen-specificities and functional activity from humans, [21] [22] [23] the contribution of IgA1 proteases to bacterial survival in vivo has not been demonstrated. Thus, we investigated the ability of IgA1 protease to modify killing of S. pneumoniae by using novel IgA1 and IgA2 human monoclonal antibodies (hMAbs) specific for the pneumococcal capsule, isogenic wild-type and IgA1 protease-deficient organisms, and both in vitro and in vivo assay systems.
RESULTS

IgA1 protease inhibits IgA-dependent killing of S. pneumoniae in vitro
Pneumococcal capsule-specific hMAbs of the IgA1 and IgA2 subclasses can kill wild-type S. pneumoniae in vitro (reduce the number of bacterial colony-forming units (CFU)) in the presence of complement and phagocytic cells. 20 We determined the ability of IgA1 protease, which cleaves the capsule-binding variable region of IgA1 from the phagocyte-binding constant region, to disrupt killing by these antibodies. Indeed, intact capsule-specific IgA1 hMAbs supported dose-dependent killing of S. pneumoniae (Figure 1a ). However, pretreatment of the IgA1 hMAbs with IgA1 protease (available in recombinant form from H. influenzae Rd) eliminated this IgA-mediated killing of S. pneumoniae (67 ± 6% vs. 10 ± 4% kill with and without IgA1 protease preincubation, respectively; Po0.01). By contrast, the protease had no effect on killing supported by the capsule-specific IgA2 hMAbs ( Figure 1b ). IgA1 protease cleaved the heavy chain of IgA1, but not of IgA2, into lower molecular weight fragments (inserts; Figures 1a,b, respectively), although a fraction of the heavy chain remained intact. The protease had comparable inhibitory effects on killing of type 8 organisms with a type 8-specific IgA1 hMAbs (not shown). The killing resulted primarily from the opsonophagocytic activity of capsule-specific IgA and complement with neutrophils.
However, a small proportion of the decrease in CFUs in the killing results (3-5% at 75 ng ml À 1 IgA1, 11-15% at 225 ng ml À 1 ) can be ascribed to agglutination of the organisms by polymeric IgA alone rather than phagocytosis (Fasching et al. 20 and Supplementary Figure S1 ).
Consistent with the effects of preincubation of IgA1 with exogenous IgA1 protease, endogenous IgA1 protease produced directly by S. pneumoniae also inhibited such killing. Killing of protease-producing organisms required Efivefold more IgA1 hMAbs than did killing of isogenic IgA1 protease-deficient mutants (for 50% kill, 70 vs. 15 ng ml À 1 , respectively) ( Figure 1c ). By contrast, the IgA2 hMAbs supported killing of both organisms with equal efficiency (Figure 1d ). After overnight incubation, supernatant fluid from the wild-type but not the protease-deficient S. pneumoniae cleaved the heavy chain of IgA1, but not IgA2 (not shown). Thus, IgA1 protease from H. influenzae, as applied exogenously, and from S. pneumoniae, produced endogenously, diminished the ability of human IgA1 to support killing of S. pneumoniae by phagocytes with complement.
Binding of IgA to S. pneumoniae in vitro
We considered whether IgA1 protease inhibited binding of the heavy chain alone or the whole IgA1 antibody to the organism. Preincubation of capsule-specific IgA1 hMAbs with exogenous recombinant IgA1 protease significantly reduced the amount of IgA1 heavy chain bound to S. pneumoniae to 9% of that with intact IgA1 as detected by IgA1-specific detector antibody (Figure 2a) . Similarly, exposure of the IgA1 hMAbs to pneumococcal IgA1 protease produced endogenously over 90 min by the organism during incubation also decreased detectable bound IgA1 by 43%. However, cleavage of IgA1 by the protease did not affect binding of the light chain and likely the F(ab) fragment to the organism (Figure 2c ). We next considered whether the effects of the endogenously produced protease on IgA1 were due to enzymatic activity expressed on the bacterial cell surface or released into solution. When specific monoclonal IgA1 was incubated with live wildtype S. pneumoniae for 90 min, less than half the IgA1 heavy chain was detected on the bacterial surface with the anti-IgA1 detector antibody compared with that bound to heat-killed organisms ( Figure 2b ). However, incubation of IgA1 hMAbs with heat-killed organisms caused no such decrement in bound antibody, suggesting that the protease is heat-labile or the activity required active production. Moreover, co-incubation of IgA1-opsonized heat-killed fluorescein isothyocyanate (FITC)tagged organisms with an equal number of untagged and unopsonized live IgA1 protease-producing organisms over the same period also resulted in no decrement in IgA1 detection on the heat-killed bacterial surface. Thus, the proteolytic effects of IgA1 protease on capsule-specific IgA1 bound to bacteria appears to occur primarily on IgA1 bound to the cell surface of living bacteria and are not due to effects of release of the enzyme into the fluid phase of the culture medium. 15 Consistent with this observation, IgA1 protease is anchored to the cell surface and not actively secreted. 24 However, IgA1 bound to S. pneumoniae can be cleaved by soluble IgA1 protease added to the media so that bound antibody is not protected from cleavage by exogenous enzyme (data not shown). Whether live organisms can produce enough, and release sufficient, IgA1 protease to cleave the antibody on neighboring organisms in vivo has not been proven to date.
IgA1 protease eliminates IgA1-mediated protection against S. pneumoniae in vivo
We compared the ability of the two capsule-specific hMAbs, each of which supported killing of S. pneumoniae in vitro, to provide passive protection against fatal infection in vivo. After intraperitoneal administration of the protease-resistant IgA2 hMAbs, 81% of mice given intranasal challenge of wild-type S. pneumoniae survived at 72 h compared with 10% of those pretreated with IgA1 hMAbs or 17% of those given phosphate-buffered saline control (Po0.0001; Figure 3a ). However, levels of the two hMAbs achieved in mouse sera after passive immunization were comparable over time ( Figure 3b ). No human IgA was detected in the nares. These IgA subclassrelated differences in survival were associated with differences in the ability of sera from mice passively immunized with IgA1 and IgA2 hMAbs to support complement-dependent killing by phagocytes in vitro ( Figure 3c ). The IgA1 hMAbs in mouse sera from the earliest time point (4 h), which contained the highest hMAb level, killed the IgA1 protease-producing wild-type organism effectively (right column pair; black bar). However, this activity declined over time as antibody levels declined (right column pair; grey bar). By contrast, these same sera consistently supported killing of an isogenic IgA1 protease-deficient mutant at both time points examined (second column pair).
With the protease-resistant IgA2 hMAbs, killing of both organisms was comparable at each time and antibody concentration (first and third column pairs). In addition, a serotype-specific IgG1 MAb also showed similar killing of both wild-type and mutant organisms (not shown). The heat-inactivated mouse serum had no activity against the organisms. Thus, the pneumococcal protease appears to specifically target human IgA1 and not other aspects of phagocyte-dependent killing. Finally, we considered the possibility that differences in the activity of IgA1 and IgA2 hMAbs accounted for the differential protection afforded by the two hMAbs, rather than their susceptibility to cleavage by IgA1 protease or in the virulence of the organisms. Indeed, the IgA2 hMAbs supported killing more efficiently than did the IgA1 hMAbs in vitro (Figures 1a,c) . However, passive immunization of mice with the IgA1 hMAbs was associated with 50% survival at 72 h when the mice were infected with the protease-deficient mutant, but only 10% when infected with the isogenic protease-producing parent (Po0.005; Figure 4 ). Moreover, in the absence of antibody, the virulence of these isogenic organisms was not significantly different for the protease-deficient vs. wild-type strains, as reflected by the lethal dose 50 (LD 50 : 3 Â 10 6 CFU and 1 Â 10 7 CFU, respectively) by Reed-Muench analysis 25 with intranasal infection. Moreover, the in vitro growth curves of the two organisms were similar (not shown). Therefore, production of IgA1 protease by the organisms, and the susceptibility of the hMAbs to protease cleavage, was closely associated with the ability of the capsule-specific IgA antibodies to protect against this encapsulated pathogen in vitro and in vivo.
Human immune IgG inhibits IgA1 protease
Preincubation of IgA1 with pneumococcal IgA1 protease substantially reduced detection of the hinge region with a hinge-specific murine monoclonal antibody by immunoblot (Figure 5a ; controls). Using this detection system for protease activity, purified IgG from convalescent sera from two representative patients obtained 1 month after resolution of pneumococcal bacteremia inhibited the protease activity, allowing detection of the hinge region. Acute sera from these patients showed no inhibition of protease activity, so the hinge region was not detected.
Among 11 patients surviving bacteremic pneumococcal pneumonia and tested within 2-7 days of the onset of symptoms, two (18%) (both capsular serotype 14) had detectable IgA1 protease-inhibiting activity in acute sera drawn within 3 days of admission (Figure 5b) . In convalescent sera drawn 3-4 weeks after infection, 7 of 11 (64%) patients, including the 2 with detectable activity in acute sera, generated significantly increased titers of IgA1 protease-inhibiting IgG. Median titers of IgA1 protease-neutralizing activity rose from 1:3 to 1:20 in acute and convalescent sera, respectively. The serum IgG concentrations required for inhibition of IgA1 protease activity ranged from 1.2 to 10 mg ml À 1 (total serum IgG levels were 8-12 mg ml À 1 ). Among these samples, neutralizing activity was largely independent of the serotype of the infecting organisms. Four of these patients were infected with serotype 14 S. pneumoniae isolated from blood during their acute bacteremia, and one each had types 1, 4 and 8. These data suggest neutralizing antibodies elicited during natural infection may inhibit the proteolytic activity of bacterial IgA1 proteases. The inability to generate neutralizing activity in four patients may have been related to antigenic differences between the proteases 26 or an inability of these patients to respond.
DISCUSSION
By exploiting the functional activity of novel serotype-matched human IgA1 and IgA2 hMAbs, we show that IgA1 protease compromises the ability of the capsule-specific IgA1 to provide protection against S. pneumoniae both in vitro and in vivo. For decades, IgA1 proteases have been proposed to enhance the pathogenicity of invasive mucosal bacteria. 16, 17, 27 Different bacterial species express functionally similar proteases that cleave the human IgA1 hinge region after a sequence of specific proline residues, but the proteases have completely different catalytic mechanisms. 17 This apparent ''convergent evolution'' of the enzyme activity among the many different mucosal bacterial pathogens 17 suggests that the activity promotes bacterial survival. However, there has been no direct demonstration of the importance of bacterial IgA1 proteases in vivo, because the native IgA of animals used for these experiments is not a substrate for the IgA proteases. Experimental human urethral infection was successful with an IgA1 protease mutant of Neisseria gonorrhoeae, but IgA1 is not the predominant IgA subclass at this site. 28 In addition, the mechanism(s) by which the protease accomplishes a benefit to the bacteria in vivo had not been demonstrated.
The majority of bacteria producing IgA-cleaving proteases colonize the oral and upper respiratory mucosa where IgA1 predominates. 29, 30 Thus, IgA1 protease from S. pneumoniae may contribute to the bacteria's ability to colonize and invade by impairing the function of IgA1. Consistent with this hypothesis, we have shown that pneumococcal capsule-specific IgA1 enhances, rather than inhibits, adherence of encapsulated S. pneumoniae to human respiratory epithelium in the presence of IgA1 protease. 15 Although such processes may contribute to colonization, the protease may also facilitate the development of clinical disease by other mechanisms. For example, levels of IgA1 protease activity from H. influenzae are increased in strains causing tissue injury and disease compared with those causing colonization alone. 31 The assays we employed in this study, killing by neutrophils and animal protection by systemic antibody following mucosal challenge, may be more directly related to the ability of IgA to protect against disease rather than colonization. We showed that capsule-specific human MAbs of the protease-resistant IgA2 subclass are equal in supporting the killing of wild-type and protease-deficient mutant organisms, a result that suggests that pneumococcal IgA protease does not appear to impair the phagocytic function of the neutrophils themselves in these settings. In related studies, we have also not identified significant differences in the virulence for mice of isogenic wild-type or protease-deficient mutants of S. pneumoniae serotype 2. 32 However, that IgA1 protease did influence survival of infected mice in other reports [33] [34] [35] suggests that such differences may depend on the inoculum (less effect at higher inoculum), the bacterial serotype (type 4 and 19F vs. type 2), the strain of mice (out bred MF1 and inbred BALB/c vs. out bred specific pathogen-free Swiss mice), the clinical model (pneumonia vs. bacteremia), and perhaps the specific molecular deletion, each of which differed from our studies. That mice do not produce IgA that is susceptible to IgA1 protease suggests other functions for the protein in bacterial pathogenesis.
The reduction in killing activity by IgA1 following the cleavage of its heavy polypeptide chain by IgA protease is likely due to the known dissociation of the effector domains of the antibody, unlinking the Fca CH2/3 fragments that are essential for binding to Fca receptors (CD89) on neutrophils and alveolar macrophages from the bacterial-binding Fab domains. [36] [37] [38] These Fca CH2/3 domains have been associated with complement activity in both the polymeric and secretory forms of IgA. 39, 40 In addition, protease cleavage yields Fab domains that appear to continue to bind to antigens on the bacterial surface. However, the monomeric Fab binding would not foster the formation of aggregates that would support bacterial clearance, which depends on the Fc region of the antibody. 41 Although we have focused on killing and invasive infection, the protease may well also limit agglutination, enhance adherence 15 and potentially killing at mucosal sites, activities currently under investigation.
Unlike the IgA1 proteases of Gram-negative pathogenic microorganisms that are secreted into the medium, the protease produced by S. pneumoniae does not appear to be actively secreted but apparently reaches the medium only when cell lysis has taken place. The IgA1 protease of S. pneumoniae is predominantly bacterial cell surface-associated through an unusual sortase A-dependent, non-covalent mechanism of attachment 24 Our data confirm recent studies that the activity of the protease that is retained at the bacterial surface may have substantial impact on specific pneumococcal capsule-specific antibodies that are directly bound to the pathogen. By contrast, a protease secreted in free form into the medium may be expected to have a more generalized effect on IgA in the mucosal environment, thus facilitating IgA1 evasion by other microbes that are competing for the same niche. 9, 15, 32 We demonstrate that the activity of IgA1 protease can be inhibited by serum IgG antibodies arising during convalescence from invasive pneumococcal disease. This neutralization of proteolytic activity aligns with earlier observations that antibodies that bind 42 and block activity of the proteases of Neisseriae, H. influenzae, and other species [43] [44] [45] can be found in serum and secretions, such as breast milk and nasal fluids. Romanello et al. 46 showed that sera from patients with invasive pneumococcal disease recognized recombinant pneumococcal IgA protease proteins, but these investigators did not report that these antibodies inhibited the enzyme activity. The impact of our results may be limited by the antigenic diversity of IgA1 proteases that has been found among clinical pneumococcal isolates, both between and within serotypes. 26 Ongoing functional and sequencing data with these strains will determine whether the proteolytic regions and neutralizing domains are most well conserved. 47 The immunological consequences of protease heterogeneity can be determined with greater numbers of patients and a more thorough understanding of proteolytic motifs and inhibitory epitopes. Nevertheless, our results highlight the potential of IgA1 protease as a vaccine candidate that may limit colonization on mucosal surfaces served by secretory IgA1 antibodies and that may reduce the incidence of invasive disease and local mucosal infections caused by this important bacterial pathogen.
In summary, IgA1 proteases produced by S. pneumoniae, and other invasive mucosal pathogens, may enable the bacteria to evade killing by capsule-specific IgA by sabotaging the effector function of the specific humoral immune response. This proteolytic activity of the pneumococcal enzyme appears to be primarily cell-associated and directed to pathogenspecific IgA antibodies bound to the organism. However, this activity is only one element of the host-pathogen interaction in which the pathogen attempts to establish a niche in the context of robust host defense. Following colonization, S. pneumoniae can elicit a local and/or systemic IgA1 response to the bacterial surface. 30, 48 As demonstrated here, the pathogen produces IgA1 protease that limits the protective effects of this antibody. In turn, the host then generates a specific antibody response in blood (or mucosa) that neutralizes the proteolytic activity of the enzyme. The interplay between bacterial virulence factors and the host's successive ability to circumvent them likely determines the outcome of these common and often serious infections.
METHODS
S. pneumoniae strains. Strains included wild-type S. pneumoniae isolates of serotypes 2 (ATCC 6302) and 8 (ATCC 6308) (American Tissue Culture Collection; Mannassas, VA), and paired isogenic serotype 2 wild-type and insertion-deletion IgA1 protease mutant organisms, which yielded a nonfunctional truncated IgA1 protease gene product (strains P210 and P354, respectively). 32 IgA1 protease. We used recombinant IgA1 protease from an unencapsulated H. influenzae strain Rd mutant with a nickel-binding 6 Â His epitope replacement 44 (recombinant pneumococcal IgA1 protease not available), and partially purified pneumococcal IgA1 protease, derived by differential precipitation (30 and 60% ammonium sulfate) of supernatants of log-phase S. pneumoniae type 14 (ATCC 6314) in Todd-Hewitt broth. 49 Enzymatic activity was confirmed using silver-stained denaturing polyacrylamide gel electrophoresis (12%) of IgA1 and IgA2 hMAb fragments before and after overnight incubation with IgA1 protease.
hMAbs to pneumococcal capsular polysaccharides. hMAbs specific for S. pneumoniae serotypes 2 (IgA1 (2A02), IgA2 (2A01), IgG1 (2G01)), and serotype 8 (IgA1 (8A01)) were purified to 498.5% purity from B cells of recently immunized healthy adults that had been fused with the K6H6/B5 mouse-human heteromyeloma and cloned 3 Â by limiting dilution, as described. 15, 18, 50, 51 Consistent with results with capsule-specific IgA in serum, the majority of the MAb IgA is in the polymeric molecular form. 18, 20, 52 In vitro killing assay. Log-phase S. pneumoniae serotypes 2 (ATCC 6302, P210, P354) or 8 (ATCC 6308) were incubated with hMAbs for 30 or 120 min, then 1 h with baby rabbit complement (10%) and human neutrophils (500:1, neutrophil:bacteria) with shaking. 18 CFU were determined from serial dilutions on blood agar plates. Percentage of kill was determined by: (1 À (CFU in wells with MAb per CFU in wells without MAb)) Â 100.
Murine protection model. In protocols approved by the animal research committee, after inhaled isoflurane anaesthesia, specific pathogen-free Swiss out bred mice in a pathogen-free barrier facility were inoculated intranasally with 2 Â 10 7 log-phase CFU bacterial suspension (E2 Â LD 50 ) 4 h after an intraperitoneal dose of human capsule-specific hMAbs (2 mg) or saline placebo. Survival was recorded every 8 h until killing at 72 h. 53 IgA-bacterial binding assays. S. pneumoniae serotype 2 strains (ATCC 6302 and P210) were incubated 30 min with capsule-specific IgA1 hMAbs that had or had not been digested overnight by recombinant IgA1 protease. Alternatively, an IgA1 proteaseproducing wild-type strain (P210) was incubated with intact capsule-specific IgA1 hMAbs for 30 min, washed, and incubated for 90 min. Bacteria were stained with mouse anti-human IgA1-biotin (Southern Biotechnology Associates, Birmingham, AL), followed by streptavidin (SA)-allophycocyanin (BD Pharmingen, San Diego, CA). The mean fluorescent intensities of the bacteria, identified by forward and side scatter, were compared (FACSVantage cytometer; Becton Dickinson, Mansfield, MA) using control antibodies matched for species, source, isotype, and fluorescent label and compensation control beads. The mouse anti-IgA1 neither recognized bound IgG or any variable region of the immunoglobulin heavy chain regions that might be shared by IgA and IgG antibodies nor its associated k or l light chains (data not shown).
To consider whether the cleavage of the IgA1 occurred on the bacterial surface or in the fluid phase, live unlabeled or dead FITC-tagged wild-type S. pneumoniae type 2 were opsonized with specific IgA1 hMAbs for 30 min at 37 1C and washed. Three populations of bacteria (opsonized live, opsonized dead, or opsonized FITC-tagged dead þ unopsonized live) were incubated for an additional 90 min and stained. Dead bacteria were segregated by gating on FITC þ events. Mean fluorescent intensities for bound IgA1 were compared between groups.
Inhibition of IgA1 protease cleavage by human IgG. Sera were obtained with protocols approved by the relevant institutional review boards at admission to the Minneapolis Veterans Affairs Medical Center and from convalescent sera 3-4 weeks later from 11 adult patients with bacteremic pneumococcal pneumonia (blood stream infection) and symptoms for 2-7 days but without HIV-1 infection or obvious humoral immune defects. We purified IgG (purity 498%) from IgA-depleted acute sera exactly as described from our laboratory. 18 Pneumococcal protease was preincubated with purified IgG dilutions (initial 20 mg IgG ml À 1 ) for 15 min at 37 1C, then incubated with 2.5 mg of purified control serum IgA (498% pure) for 2 h. Inhibition of cleavage was determined by the percentage of loss of heavy chain by densitometry on reducing 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and by detection or loss of the IgA1 hinge with mouse anti-human IgA1-biotin by immunoblot.
Statistics. Survival of animals in the treatment groups was compared using Cox regression analysis, and if statistically significant differences were found, survival curves were compared by log-rank test. Statistical comparisons were calculated using SPSS for Windows 6.1 (IBM, Chicago, IL).
